+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4775717
  • Report
  • Region: Global
  • 101 pages
  • IMARC Group
1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Alere Inc.
  • Becton
  • bioMérieux SA
  • Cepheid Inc.
  • Dickinson and Company
  • MORE
The global hospital acquired disease testing market was worth US$ 876 Million in 2018. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients' own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, the market value is projected to reach US$ 2,190 Million by 2024, exhibiting a CAGR of around 16.5% during 2019-2024.

Market Summary:

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital acquired disease testing market in any manner.

Key Questions Answered in This Report:

How has the global hospital acquired disease testing market performed so far and how will it perform in the coming years?
What are the key regions in the global hospital acquired disease testing market?
What is the breakup of the global hospital acquired disease market on the basis of indication?
What are the various stages in the value chain of the global hospital acquired disease testing market?
What are the key driving factors and challenges in the global hospital acquired disease testing market?
What is the structure of the global hospital acquired disease testing market and who are the key players?
What is the degree of competition in the global hospital acquired disease testing market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Alere Inc.
  • Becton
  • bioMérieux SA
  • Cepheid Inc.
  • Dickinson and Company
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Indication
5.4 Market Breakup by Region
5.5 Market Forecast
5.6 SWOT Analysis
5.6.1 Overview
5.6.2 Strengths
5.6.3 Weaknesses
5.6.4 Opportunities
5.6.5 Threats
5.7 Value Chain Analysis
5.8 Porters Five Forces Analysis
5.8.1 Overview
5.8.2 Bargaining Power of Buyers
5.8.3 Bargaining Power of Suppliers
5.8.4 Degree of Competition
5.8.5 Threat of New Entrants
5.8.6 Threat of Substitutes
5.9 Price Analysis

6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast

7 Market Breakup by Region
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast

8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMérieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories
  • Alere Inc.
  • Becton
  • Dickinson and Company
  • bioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • QIAGEN
  • Siemens Healthcare
  • Diatherix Laboratories Inc.
  • Meridian Bioscience Inc.
  • Thermo Fisher Scientific Inc. (Life Technologies Corporation)
  • Cepheid Inc.
Note: Product cover images may vary from those shown
Adroll
adroll